# MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

> **NCT03916679** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** anti-MESO CAR-T cells

## Key facts

- **NCT ID:** NCT03916679
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-20
- **Primary completion:** 2022-04-20
- **Final completion:** 2023-04-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916679, "MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03916679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*